Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 121 Lung Neoplasms 49 Triple Negative Breast Neoplasms 35 Breast Neoplasms 33 Small Cell Lung Carcinoma 29 Squamous Cell Carcinoma of Head and Neck 24 Ovarian Neoplasms 24 Neoplasm Metastasis 21 Fallopian Tube Neoplasms 19 Endometrial Neoplasms 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 15 Neoplasms 15 Head and Neck Neoplasms 12 Colorectal Neoplasms 11 Carcinoma 10 Oropharyngeal Neoplasms 9 Esophageal Neoplasms 9 Urinary Bladder Neoplasms 8 Prostatic Neoplasms 8 Carcinoma, Transitional Cell 8 Pancreatic Neoplasms 7 Carcinoma, Squamous Cell 7 Carcinoma, Ovarian Epithelial 6 Adenocarcinoma of Lung 6 Uterine Cervical Neoplasms 5 Mouth Neoplasms 5 Mesothelioma 5 Lung Diseases 5 Laryngeal Neoplasms 5 Respiratory Tract Neoplasms 4

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Carboplatin × 90 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡